Carregant...
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval
Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog. MP is a recombinant immunotoxin that consists of an anti-CD2...
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6784515/ https://ncbi.nlm.nih.gov/pubmed/31594764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000507 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|